# A Drug-Drug Interaction Study Between XW003 and Metformin, Warfarin, Rosuvastatin or Digoxin

> **NCT06335134** · PHASE1 · COMPLETED · sponsor: **Hangzhou Sciwind Biosciences Co., Ltd.** · enrollment: 57 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** XW003 injection
- **DRUG:** Metformin
- **DRUG:** Warfarin
- **DRUG:** Rosuvastatin
- **DRUG:** Digoxin

## Key facts

- **NCT ID:** NCT06335134
- **Lead sponsor:** Hangzhou Sciwind Biosciences Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-14
- **Primary completion:** 2024-01-08
- **Final completion:** 2024-06-28
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2025-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06335134

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06335134, "A Drug-Drug Interaction Study Between XW003 and Metformin, Warfarin, Rosuvastatin or Digoxin". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06335134. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*